title: Re: AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer.
authors.affiliation: Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada.
authors.forename: Maxine
authors.initials: M
authors.lastname: Sun
authors.affiliation: Vattikuti Urology Institute and VUI Center for Outcomes Research Analytics and Evaluation, Henry Ford Hospital, Detroit, MI, USA. Electronic address: firas.abdollah@gmail.com.
authors.forename: Firas
authors.initials: F
authors.lastname: Abdollah
mesh_terms: D000737:Androstenols / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D006801:Humans; D008297:Male; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives*; D011471:Prostatic Neoplasms / Q000235:genetics*; D012334:RNA, Neoplasm / Q000032:analysis*; D011944:Receptors, Androgen / Q000235:genetics*
chemical_list: D000737:Androstenols; D012334:RNA, Neoplasm; D011944:Receptors, Androgen; D010669:Phenylthiohydantoin